Loxo Oncology Inc (NASDAQ:LOXO) insider Naarden Jacob Van sold 10,000 shares of the company’s stock in a transaction on Tuesday, November 27th. The shares were sold at an average price of $147.97, for a total transaction of $1,479,700.00. Following the completion of the transaction, the insider now owns 19,200 shares of the company’s stock, valued at $2,841,024. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Naarden Jacob Van also recently made the following trade(s):
- On Thursday, October 4th, Naarden Jacob Van sold 10,000 shares of Loxo Oncology stock. The shares were sold at an average price of $165.13, for a total value of $1,651,300.00.
- On Thursday, September 13th, Naarden Jacob Van sold 10,000 shares of Loxo Oncology stock. The stock was sold at an average price of $166.32, for a total value of $1,663,200.00.
Shares of Loxo Oncology stock opened at $135.00 on Friday. Loxo Oncology Inc has a 12-month low of $75.78 and a 12-month high of $208.95. The company has a market cap of $4.14 billion, a PE ratio of -25.42 and a beta of 2.21.Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.24). The company had revenue of $42.47 million for the quarter, compared to the consensus estimate of $38.55 million. Loxo Oncology had a negative return on equity of 16.42% and a negative net margin of 43.49%. During the same quarter in the prior year, the company earned ($2.45) EPS. On average, research analysts forecast that Loxo Oncology Inc will post -2.34 earnings per share for the current year.
A number of research analysts have issued reports on the company. Zacks Investment Research cut Loxo Oncology from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. Guggenheim began coverage on Loxo Oncology in a report on Monday, September 17th. They issued a “neutral” rating for the company. JMP Securities cut their price target on Loxo Oncology from $221.00 to $215.00 and set a “buy” rating for the company in a report on Tuesday, November 13th. Leerink Swann initiated coverage on Loxo Oncology in a research report on Monday, September 24th. They issued an “outperform” rating and a $205.00 price objective for the company. Finally, Cowen reiterated a “buy” rating on shares of Loxo Oncology in a research report on Monday, October 22nd. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $189.38.
Several hedge funds have recently bought and sold shares of the stock. Cambridge Investment Research Advisors Inc. grew its holdings in Loxo Oncology by 12.8% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 2,775 shares of the biopharmaceutical company’s stock valued at $474,000 after buying an additional 315 shares in the last quarter. First Mercantile Trust Co. grew its holdings in Loxo Oncology by 45.8% in the 3rd quarter. First Mercantile Trust Co. now owns 1,029 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 323 shares in the last quarter. American International Group Inc. grew its holdings in Loxo Oncology by 3.2% in the 3rd quarter. American International Group Inc. now owns 17,845 shares of the biopharmaceutical company’s stock valued at $3,048,000 after buying an additional 549 shares in the last quarter. Voya Investment Management LLC grew its holdings in Loxo Oncology by 0.4% in the 2nd quarter. Voya Investment Management LLC now owns 186,422 shares of the biopharmaceutical company’s stock valued at $32,340,000 after buying an additional 661 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in Loxo Oncology by 5.9% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 12,559 shares of the biopharmaceutical company’s stock valued at $2,179,000 after buying an additional 700 shares in the last quarter. 96.81% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Naarden Jacob Van Sells 10,000 Shares of Loxo Oncology Inc (LOXO) Stock” was originally published by PressOracle and is the sole property of of PressOracle. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://pressoracle.com/news/2018/12/08/insider-selling-loxo-oncology-inc-loxo-insider-sells-1479700-00-in-stock.html.
About Loxo Oncology
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Further Reading: Understanding the different types of bonds
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.